Diğer
BibTex RIS Kaynak Göster

Inflammatory arthritis during immune checkpoint inhibitors therapy: case report

Yıl 2019, , 64 - 66, 25.10.2019
https://doi.org/10.19161/etd.648914

Öz

Nowadays, technological and scientific developments in modern medicine have enabled the emergence of new treatment strategies in the treatment of solid and hematologic malignancies. One group of these developments is, also called cancer immunotheraphy, Immune Checkpoint Inhibitors (ICI) thatareused in laterstages of tumors. ICI’s are monoclonal antibodies that allow cancercells to be killed by natural and adaptive immunity, especially T lymphocytes via activation or inhibition of the co-receptors. However, cancer immunotherapy can lead to activation of the immunecells to host’s healthy cells by eliminating self-tolerance, and to start series of immune reactions. Here, we aimed to present a case of inflammatory arthritis during cancer immunotherapy. 

Kaynakça

  • Duzgun O, Sarici IS, Gokcay S, et al. Effects of nivolumab in peritoneal carcinamatosis of malign melanoma in mouse model. Acta Cir Bras 2017;32(12):1006-12.
  • Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372(4):320-30.
  • Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
  • GirouxLeprieur E, Dumenil C, Julie C, et al. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Eur J Cancer 2017;78:16-23.
  • Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158-68.
  • Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immunecheckpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5(1):95. doi: 10.1186/s40425-017-0300-z.
  • Teixidor E, Sais E, Vásquez CA, at al. Immune-related adverse events and atypical radiological response with checkpoint inhibitör immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma. Oncotarget 2018;9(68):33043-9.
  • Cappelli LC, Gutierrez AK, Baer AN, at al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76(1):43-50.

Kanser immünoterapisi sırasında gelişen inflamatuvar artrit olgusu

Yıl 2019, , 64 - 66, 25.10.2019
https://doi.org/10.19161/etd.648914

Öz

Günümüzde modern tıpta yaşanan teknolojik ve bilimsel gelişmeler solid ve hematolojik malignitelerin tedavisinde yeni tedavi stratejilerin ortaya çıkmasını sağlamıştır. Bu gelişmelerden biri de kanser immünoterapisi olarak adlandırılan ve ileri evre tümörlerin tedavisinde kullanılan İmmün Checkpoint İnhibitörleri’nin (İCİ) kullanımıdır. İCİ denen bu grup moleküller, kanser hücrelerinin T lenfosit başta olmak üzere doğal ve adaptif immünitenin efektör hücrelerinde bulunan koreseptörlerin aktivasyon veya inhibisiyonu ile bu hücreler tarafından öldürülmesini sağlayan monoklonal antikorlardır. Bununla birlikte kanser immünoterapisi, immünite hücreleri üzerindeki manüplasyonu nedeniyle self toleransı ortadan kaldırarak konağın sağlıklı hücrelerinin de hedef haline gelmesine ve bunlara karşı bir dizi immün reaksiyon başlamasına neden olabilmektedir. Biz de kanser immünoterapisi sırasında gelişen inflamatuvar artrit olgusunu sunmayı amaçladık.

Kaynakça

  • Duzgun O, Sarici IS, Gokcay S, et al. Effects of nivolumab in peritoneal carcinamatosis of malign melanoma in mouse model. Acta Cir Bras 2017;32(12):1006-12.
  • Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372(4):320-30.
  • Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
  • GirouxLeprieur E, Dumenil C, Julie C, et al. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Eur J Cancer 2017;78:16-23.
  • Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158-68.
  • Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immunecheckpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5(1):95. doi: 10.1186/s40425-017-0300-z.
  • Teixidor E, Sais E, Vásquez CA, at al. Immune-related adverse events and atypical radiological response with checkpoint inhibitör immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma. Oncotarget 2018;9(68):33043-9.
  • Cappelli LC, Gutierrez AK, Baer AN, at al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76(1):43-50.
Toplam 8 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Ek
Yazarlar

Tuncer Şak 0000-0001-6366-7038

Burçak Karaca 0000-0003-2638-1625

Figen Yargucu Zihni 0000-0001-7479-3582

Yayımlanma Tarihi 25 Ekim 2019
Gönderilme Tarihi 19 Ekim 2018
Yayımlandığı Sayı Yıl 2019

Kaynak Göster

Vancouver Şak T, Karaca B, Yargucu Zihni F. Kanser immünoterapisi sırasında gelişen inflamatuvar artrit olgusu. ETD. 2019:64-6.

1724617243172472652917240      26515    

 26507    26508 26517265142651826513

2652026519